Shuttle Pharmaceuticals Holdings, Inc. (SHPH) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Gaithersburg, MD, United States. Le PDG actuel est Christopher Robert Cooper.
SHPH a date d'introduction en bourse 2022-08-31, 9 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $990.36K.
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
